clinical trial · NCT06843239
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Systemic Sclerosis (SSc)SclerodermaTibulizumabPlacebo
brief summary
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
started
Feb 6, 2025
primary completion
May 1, 2027
completion
Jan 1, 2028
last updated
Feb 12, 2026
official title
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol